Team McCallum

R&D for Lifetime of Life

Combo drugs for lung cancer.

Prof Roy Herbst reported on improvements in advanced non-small cell lung cancer (NSCLC) in phase III clinical trials where docetaxel was combined with vandetanib (Zactima).

This combination targets both the tumour itself and the blood vessels supplying the tumour.

The main benefit was an increase in the time free from disease progression. However, the overall survivial rate did not improve significantly. Women responded better than men to this combination treatment.

The question now is whether this combination confers any benefits over another option – erlotinib (Tarceva).

It is unlikely to be progressed unless additional biomarkers can be found to indicate which patients would really benefit from combined treatment.

Click here to see Combo drugs in leukaemia, another study that suggests this combo approach may yield results in the future.


June 5, 2010 - Posted by | Cancer, Medicine/Treatment, Roy Herbst, Science

1 Comment »

  1. […] « Previous | Next » […]

    Pingback by Combo drugs for leukaemia. « Team McCallum | June 5, 2010 | Reply

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: